Arnold, Carrie
2020-07-23T20:27:43Z
2020-07-23T20:27:43Z
2020
https://doi.org/10.1016/S0262-4079(20)30600-X
http://hdl.handle.net/20.500.12010/11067
POTTERING around her kitchen on the
morning of 31 December, Kate Broderick
scrolled through the headlines while
she waited for her tea to brew. One story caught
her eye: a mysterious outbreak of severe
pneumonia in Wuhan, China. Nearly overnight,
the number of cases seemed to explode.
“I knew we didn’t have time to wait,” she says.
A molecular geneticist at Inovio
Pharmaceuticals in California, Broderick was
poised for what came next. When Chinese
officials published the genetic sequence of
the new SARS-CoV-2 coronavirus causing the
illness just two weeks after the first cases were
reported to the World Health Organization,
Broderick got to work. Within 3 hours, her
team had a prototype vaccine ready for initial
testing. It was an unprecedented turnaround,
but a moment Broderick and many others
had long seen coming.
Making vaccines usually takes a decade or
more between development, safety testing
and manufacturing, says Seth Berkley, head
of Gavi, an international group that promotes
vaccine use around the world. With global
confirmed cases of the new disease, covid-19,
surging past 180,000 as this went to press,
time is of the essence.
4 páginas
image/jepg
The New Scientist
reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
Vaccine
COVID-19
Race for a vaccine
Artículo
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/acceptedVersion
https://doi.org/10.1016/S0262-4079(20)30600-X